342 related articles for article (PubMed ID: 25324168)
1. Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
Kato Y
Brain Tumor Pathol; 2015 Jan; 32(1):3-11. PubMed ID: 25324168
[TBL] [Abstract][Full Text] [Related]
2. Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
Kato Kaneko M; Ogasawara S; Kato Y
Tohoku J Exp Med; 2013 Jun; 230(2):103-9. PubMed ID: 23782684
[TBL] [Abstract][Full Text] [Related]
3. A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation.
Kato Y; Natsume A; Kaneko MK
Biochem Biophys Res Commun; 2013 Mar; 432(4):564-7. PubMed ID: 23485467
[TBL] [Abstract][Full Text] [Related]
4. Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations.
Kaneko MK; Morita S; Tsujimoto Y; Yanagiya R; Nasu K; Sasaki H; Hozumi Y; Goto K; Natsume A; Watanabe M; Kumabe T; Takano S; Kato Y
Biochem Biophys Res Commun; 2013 Mar; 432(1):40-5. PubMed ID: 23376717
[TBL] [Abstract][Full Text] [Related]
5. Novel monoclonal antibodies GMab-r1 and LMab-1 specifically recognize IDH1-R132G and IDH1-R132L mutations.
Kaneko MK; Tsujimoto Y; Hozumi Y; Goto K; Kato Y
Monoclon Antib Immunodiagn Immunother; 2013 Jun; 32(3):224-8. PubMed ID: 23750482
[TBL] [Abstract][Full Text] [Related]
6. A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma.
Liu X; Ogasawara S; Kaneko MK; Oki H; Hozumi Y; Goto K; Takagi M; Kato Y
Biochem Biophys Res Commun; 2015 Apr; 459(4):636-42. PubMed ID: 25753205
[TBL] [Abstract][Full Text] [Related]
7. Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation.
Kaneko MK; Tian W; Takano S; Suzuki H; Sawa Y; Hozumi Y; Goto K; Yamazaki K; Kitanaka C; Kato Y
Biochem Biophys Res Commun; 2011 Mar; 406(4):608-13. PubMed ID: 21352804
[TBL] [Abstract][Full Text] [Related]
8. A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas.
Fujii Y; Ogasawara S; Oki H; Liu X; Kaneko MK; Takano S; Kato Y
Biochem Biophys Res Commun; 2015 Oct; 466(4):733-9. PubMed ID: 26381180
[TBL] [Abstract][Full Text] [Related]
9. Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone.
Kato Kaneko M; Liu X; Oki H; Ogasawara S; Nakamura T; Saidoh N; Tsujimoto Y; Matsuyama Y; Uruno A; Sugawara M; Tsuchiya T; Yamakawa M; Yamamoto M; Takagi M; Kato Y
Cancer Sci; 2014 Jun; 105(6):744-8. PubMed ID: 24898068
[TBL] [Abstract][Full Text] [Related]
10. Multi-specific monoclonal antibody MsMab-2 recognizes IDH1-R132L and IDH2-R172M mutations.
Ogasawara S; Kaneko MK; Tsujimoto Y; Liu X; Kato Y
Monoclon Antib Immunodiagn Immunother; 2013 Dec; 32(6):377-81. PubMed ID: 24328739
[TBL] [Abstract][Full Text] [Related]
11. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H
PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614
[TBL] [Abstract][Full Text] [Related]
12. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation.
Kato Y; Jin G; Kuan CT; McLendon RE; Yan H; Bigner DD
Biochem Biophys Res Commun; 2009 Dec; 390(3):547-51. PubMed ID: 19818334
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic advantage of double immunohistochemistry using two mutation-specific anti-IDH antibodies (HMab-1 and MsMab-1) in gliomas.
Takano S; Kato Y; Yamamoto T; Liu X; Ishikawa E; Kaneko MK; Ogasawara S; Matsuda M; Noguchi M; Matsumura A
Brain Tumor Pathol; 2015 Jul; 32(3):169-75. PubMed ID: 25652153
[TBL] [Abstract][Full Text] [Related]
14. Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.
Liu X; Kato Y; Kaneko MK; Sugawara M; Ogasawara S; Tsujimoto Y; Naganuma Y; Yamakawa M; Tsuchiya T; Takagi M
Cancer Med; 2013 Dec; 2(6):803-14. PubMed ID: 24403254
[TBL] [Abstract][Full Text] [Related]
15. Determining IDH-Mutational Status in Gliomas Using IDH1-R132H Antibody and Polymerase Chain Reaction.
Gondim DD; Gener MA; Curless KL; Cohen-Gadol AA; Hattab EM; Cheng L
Appl Immunohistochem Mol Morphol; 2019; 27(10):722-725. PubMed ID: 30358614
[TBL] [Abstract][Full Text] [Related]
16. Isocitrate dehydrogenase mutations in gliomas.
Waitkus MS; Diplas BH; Yan H
Neuro Oncol; 2016 Jan; 18(1):16-26. PubMed ID: 26188014
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemistry using monoclonal antibody MsMab-2 is useful to detect IDH1 R132L in intrahepatic cholangiocarcinoma.
Hayashi A; Misumi K; Shibahara J; Kokudo N; Kato Y; Fukayama M
Pathol Int; 2016 Oct; 66(10):578-582. PubMed ID: 27595804
[TBL] [Abstract][Full Text] [Related]
18. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Ward PS; Patel J; Wise DR; Abdel-Wahab O; Bennett BD; Coller HA; Cross JR; Fantin VR; Hedvat CV; Perl AE; Rabinowitz JD; Carroll M; Su SM; Sharp KA; Levine RL; Thompson CB
Cancer Cell; 2010 Mar; 17(3):225-34. PubMed ID: 20171147
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.
Agarwal S; Sharma MC; Jha P; Pathak P; Suri V; Sarkar C; Chosdol K; Suri A; Kale SS; Mahapatra AK; Jha P
Neuro Oncol; 2013 Jun; 15(6):718-26. PubMed ID: 23486690
[TBL] [Abstract][Full Text] [Related]
20. IDH2 compensates for IDH1 mutation to maintain cell survival under hypoxic conditions in IDH1‑mutant tumor cells.
Zhang Y; Lv W; Li Q; Wang Q; Ru Y; Xiong X; Yan F; Pan T; Lin W; Li X
Mol Med Rep; 2019 Aug; 20(2):1893-1900. PubMed ID: 31257503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
